Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children

Table 3 Comparison between patients with sustained virological response and non-sustained virological response according to different variables n (%)

Parameter	SVR	Non-SVR	P value
	(n = 11)	(n = 33)
Center:
CUPH	1 (9)	9 (27.3)	0.330
YAGCC	5 (45.5)	13 (39.4)
NLI	5 (45.5)	11 (33.3)
Age (yr)	9.9 ± 3.76	10.39 ± 3.45	0.385
Male	9 (81.8)	22 (66.7)	0.340
Expected duration of infection (yr)	3.77 ± 3.28	5.61 ± 4.02	0.341
Previous treatment trial	2 (18.2)	9 (27.3)	0.546
Previous treatment type2
Short-acting IFN + RBV	2 (100)	8 (88.9)	1.000
PEG-IFN + RBV	0 (0)	1 (11.1)
Previous response type2
Non-responder	0 (0)	7 (77.8)	0.0391
Relapser	2 (100)	2 (22.2)
Possible cause of infection
Surgery	4 (36.4)	10 (30.3)	0.709
Blood transfusion	4 (36.4)	11 (33.3)	0.854
Tonsillectomy	1 (9.1)	4 (12.1)	0.784
Circumcision	9 (81.8)	22 (66.7)	0.340
Minor procedures	8 (72.7)	22 (66.7)	0.709
Vertical transmission	2 (18.2)	6 (18.2)	1.000
Family contact	4 (36.4)	14 (42.4)	0.723
Injection interval:
5 d	1 (9)	16 (48.5)	0.0201
7 d	10 (91)	17 (51.5)
Treatment duration:
48 wk	9 (81.8)	27 (81.8)	0.940
72 wk	2 (18.2)	6 (18.2)
Genotype:
4a	4 (80)	24 (77.4)	0.890
4b	1 (20)	7 (22.6)
Viral load:
Low	7 (64)	11 (33.4)	0.180
Moderate	4 (36)	20 (60.6)
High	0 (0)	2 (6.0)
Histological Activity:
Mild	11 (100)	31 (96.9)	0.550
Moderate	0 (0)	1 (3.1)
Fibrosis stage:
No	1 (9.1)	12 (37.5)	0.112
Mild	10 (90.9)	18 (56.3)
Moderate	0 (0)	2 (6.3)
Steatosis:
No	11 (100)	28 (87.5)	0.460
Mild	0 (0)	3 (9.4)
Moderate	0 (0)	1 (3.1)

¹Significant;

²Percentages were calculated for those with previous treatment trial. SVR: Sustained virological response.